Lifeward shares surge 13.87% premarket after strategic partnership with Oramed to acquire POD technology and secure $47M investment.

Lifeward surged 13.87% in premarket trading following the announcement of a strategic transaction with Oramed Pharmaceuticals. Oramed transferred its proprietary POD™ oral drug delivery platform to Lifeward, granting itself a 49.9% beneficial ownership stake and warrants. The deal includes up to $47 million in funding through convertible notes and warrants, with Oramed investing $9 million in each of two $10 million notes. Lifeward will manage its FDA-approved medical robotics products (ReWalk and AlterG, generating $26 million in the last four quarters) while leveraging Oramed’s biotech innovation. The partnership positions Lifeward to combine near-term MedTech profitability with long-term Biotech growth, supported by Mark Grant’s diabetes sector expertise. The transaction’s scale, including milestone-based funding and Oramed’s ownership stake, signals a transformative step toward diversification and profitability, directly driving the stock’s sharp premarket rise.